Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, ...

IPL is passé, and Lok Sabha elections no longer carry the same thrill. A new battle is brewing in India, and is ready to take ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

The Centres for Medicare and Medicaid Services on Friday said that it did not move forward with a proposal put forward by the ...

Trump’s latest tariff vow threatens to disrupt supplies of obesity drugs such as Mounjaro and Wegovy as pharma giants face ...

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.